La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Edwards Lifesciences Croissance future
Future contrôle des critères 2/6
Edwards Lifesciences devrait augmenter ses bénéfices et son chiffre d'affaires de 7.5% et de 8.4% par an respectivement. Le BPA devrait croître de de 5.3% par an. Le rendement des capitaux propres devrait être 23.9% dans 3 ans.
Informations clés
7.5%
Taux de croissance des bénéfices
5.3%
Taux de croissance du BPA
Medical Equipment croissance des bénéfices | 17.4% |
Taux de croissance des recettes | 8.4% |
Rendement futur des capitaux propres | 23.9% |
Couverture par les analystes | Good |
Dernière mise à jour | 16 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 7,702 | 1,956 | 1,685 | 2,020 | 15 |
12/31/2025 | 7,043 | 1,787 | 1,598 | 1,835 | 16 |
12/31/2024 | 6,481 | 1,530 | 1,376 | 1,713 | 18 |
6/30/2024 | 6,204 | 1,540 | 552 | 866 | N/A |
3/31/2024 | 6,114 | 1,428 | 251 | 528 | N/A |
12/31/2023 | 6,005 | 1,402 | 630 | 896 | N/A |
9/30/2023 | 5,362 | 1,341 | 775 | 1,042 | N/A |
6/30/2023 | 5,201 | 1,300 | 669 | 940 | N/A |
3/31/2023 | 5,279 | 1,451 | 972 | 1,239 | N/A |
12/31/2022 | 5,382 | 1,522 | 953 | 1,218 | N/A |
9/30/2022 | 5,364 | 1,459 | 1,040 | 1,309 | N/A |
6/30/2022 | 5,355 | 1,455 | 1,261 | 1,531 | N/A |
3/31/2022 | 5,357 | 1,539 | 1,428 | 1,725 | N/A |
12/31/2021 | 5,233 | 1,503 | 1,402 | 1,732 | N/A |
9/30/2021 | 5,095 | 1,477 | 1,409 | 1,758 | N/A |
6/30/2021 | 4,925 | 1,462 | 1,050 | 1,443 | N/A |
3/31/2021 | 4,474 | 851 | 717 | 1,148 | N/A |
12/31/2020 | 4,386 | 823 | 647 | 1,054 | N/A |
9/30/2020 | 4,369 | 794 | 692 | 1,057 | N/A |
6/30/2020 | 4,322 | 744 | 941 | 1,279 | N/A |
3/31/2020 | 4,484 | 1,108 | 1,087 | 1,389 | N/A |
12/31/2019 | 4,348 | 1,047 | 905 | 1,183 | N/A |
9/30/2019 | 4,152 | 774 | 809 | 1,073 | N/A |
6/30/2019 | 3,964 | 725 | 705 | 978 | N/A |
3/31/2019 | 3,821 | 765 | 523 | 777 | N/A |
12/31/2018 | 3,723 | 722 | 685 | 927 | N/A |
9/30/2018 | 3,634 | 712 | 754 | 998 | N/A |
6/30/2018 | 3,549 | 657 | 772 | 966 | N/A |
3/31/2018 | 3,447 | 560 | N/A | 1,024 | N/A |
12/31/2017 | 3,435 | 584 | N/A | 1,001 | N/A |
9/30/2017 | 3,315 | 745 | N/A | 838 | N/A |
6/30/2017 | 3,232 | 716 | N/A | 733 | N/A |
3/31/2017 | 3,150 | 657 | N/A | 726 | N/A |
12/31/2016 | 2,964 | 570 | N/A | 704 | N/A |
9/30/2016 | 2,867 | 552 | N/A | 607 | N/A |
6/30/2016 | 2,743 | 528 | N/A | 604 | N/A |
3/31/2016 | 2,601 | 515 | N/A | 584 | N/A |
12/31/2015 | 2,494 | 495 | N/A | 550 | N/A |
9/30/2015 | 2,441 | 463 | N/A | 539 | N/A |
6/30/2015 | 2,433 | 440 | N/A | 349 | N/A |
3/31/2015 | 2,391 | 874 | N/A | 957 | N/A |
12/31/2014 | 2,323 | 811 | N/A | 1,022 | N/A |
9/30/2014 | 2,241 | 777 | N/A | 1,040 | N/A |
6/30/2014 | 2,129 | 759 | N/A | 1,160 | N/A |
3/31/2014 | 2,071 | 306 | N/A | 511 | N/A |
12/31/2013 | 2,046 | 389 | N/A | 473 | N/A |
9/30/2013 | 2,020 | 405 | N/A | 476 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de EW ( 7.5% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de EW ( 7.5% par an) devraient croître plus lentement que le marché US ( 15.1% par an).
Croissance élevée des bénéfices: Les bénéfices de EW devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de EW ( 8.4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de EW ( 8.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de EW devrait être élevé dans 3 ans ( 23.9 %)